Cancer Biology

Discussions of New Developments and Updates

Skip to content
  • Home
  • About
  • Topics
    • Statistics & Epidemiology
      • Incidence
      • Mortality
      • Prevention
      • Diet & Nutrition
    • Biology
      • Cell Cycle
      • Tumor Microenvironment
      • Angiogenesis
      • Invasion & Metastasis
      • Immortalization
      • Stem Cells
      • Heterotypic Cellular Interactions
    • Signal Transduction
      • Receptor Tyrosine Kinase Inhibitors
      • Hormone Receptors
      • Growth Receptors
    • Genetics
      • Oncogenes
      • Tumor Suppressor Genes
      • Mutations
      • Epigenetic Regulation
      • DNA Repair
    • Immunology & Immunotherapy
      • Antibodies & Conjugates
      • Checkpoint Inhibitors
      • Vaccines
      • CAR-T
    • Therapy
      • Traditional Chemotherapy
      • Hormonal
      • Surgery & Radiation
      • Rational Drug Design
      • Off-Target Effects
      • Pharmacokinetics & Pharmacodynamics
      • Resistance
  • SHU Department of Biology
Cancer Biology

PD-1 inhibitor approved in Asia

Ono Pharmaceuticals announced that nivolumab has been approved in Asia.  It obtained the rights to nivolumab from Medarex in 2005.  It is approved for use in patients with unresectable melanoma.

  • Twitter
  • LinkedIn
This entry was posted in Checkpoint Inhibitors and tagged nivolumab, Ono, PD-1 on July 7, 2014 by Joseph Gulfo.

Post navigation

← Targeted Nanoparticles for Cancer – optimizing physiochemical properties for enhanced tumor-killing Enhanced ADCC technologies to improve cancer cytotoxicity →


This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

[fts_twitter twitter_name=@josephgulfo tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]
Proudly powered by WordPress

Pin It on Pinterest

Share This
  • Twitter
  • LinkedIn